{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:21:56Z","timestamp":1791292916648,"version":"4.1.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T00:00:00Z","timestamp":1634169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T00:00:00Z","timestamp":1634169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K01DA039804A"],"award-info":[{"award-number":["K01DA039804A"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["MACS\/WIHS HL146203"],"award-info":[{"award-number":["MACS\/WIHS HL146203"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s10461-021-03483-7","type":"journal-article","created":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T06:04:58Z","timestamp":1634191498000},"page":"1260-1269","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Long-Acting Injectable ART and PrEP Among Women in Six Cities Across the United States: A Qualitative Analysis of Who Would Benefit the Most"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7608-7921","authenticated-orcid":false,"given":"Morgan M.","family":"Philbin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadie","family":"Bergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrigan","family":"Parish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna","family":"Kerrigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth N.","family":"Kinnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mardge H.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwakemi","family":"Sosanya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anandi N.","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adaora A.","family":"Adimora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Cocohoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Goparaju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth T.","family":"Golub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Vaughn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Jos\u00e9 I.","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret A.","family":"Fischl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Alcaide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa R.","family":"Metsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,14]]},"reference":[{"key":"3483_CR1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/09540121.2010.507741","volume":"23","author":"V Van Tam","year":"2011","unstructured":"Van Tam V, Pharris A, Thorson A, Alfven T, Larsson M. \u201cIt is not that I forget, it\u2019s just that I don\u2019t want other people to know\u201d: barriers to and strategies for adherence to antiretroviral therapy among HIV patients in Northern Vietnam. AIDS Care. 2011;23:139\u201345.","journal-title":"AIDS Care"},{"key":"3483_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2989\/16085900609490363","volume":"5","author":"N Skhosana","year":"2006","unstructured":"Skhosana N, Struthers H, Gray G, McIntyre J. HIV disclosure and other factors that impact on adherence to antiretroviral therapy: the case of Soweto, South Africa. Afr J AIDS Res. 2006;5:17\u201326.","journal-title":"Afr J AIDS Res"},{"key":"3483_CR3","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1007\/s10461-013-0594-x","volume":"18","author":"MR Charania","year":"2014","unstructured":"Charania MR, Marshall KJ, Lyles CM, Crepaz N, Kay LS, Koenig LJ, et al. Identification of evidence-based interventions for promoting HIV medication adherence: findings from a systematic review of U.S.-based studies, 1996\u20132011. AIDS Behav. 2014;18:646\u201360.","journal-title":"AIDS Behav"},{"key":"3483_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/COH.0000000000000597","volume":"15","author":"ME Clement","year":"2020","unstructured":"Clement ME, Kofron R, Landovitz RJ. Long-acting injectable cabotegravir for the prevention of HIV infection. Curr Opin HIV AIDS. 2020;15:19\u201326.","journal-title":"Curr Opin HIV AIDS"},{"key":"3483_CR5","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/COH.0000000000000219","volume":"11","author":"RJ Landovitz","year":"2016","unstructured":"Landovitz RJ, Kofron R, McCauley M. The promise and pitfalls of long acting injectable agents for HIV prevention. Curr Opin HIV AIDS. 2016;11:122\u20138.","journal-title":"Curr Opin HIV AIDS"},{"key":"3483_CR6","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1007\/s10461-020-02929-8","volume":"24","author":"M Murray","year":"2020","unstructured":"Murray M, Antela A, Mills A, Huang J, J\u00e4ger H, Bernal E, et al. Patient-reported outcomes in ATLAS and FLAIR participants on long-acting regimens of cabotegravir and rilpivirine over 48 weeks. AIDS Behav. 2020;24:3533\u201344.","journal-title":"AIDS Behav"},{"key":"3483_CR7","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","volume":"382","author":"S Swindells","year":"2020","unstructured":"Swindells S, Andrade-Villanueva J-F, Richmond GJ, Rizzardini G, Baumgarten A, Masi\u00e1 M, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020;382:1112\u201323.","journal-title":"N Engl J Med"},{"key":"3483_CR8","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s40265-020-01326-8","volume":"80","author":"A Markham","year":"2020","unstructured":"Markham A. Cabotegravir plus rilpivirine: first approval. Drugs. 2020;80:915\u201322.","journal-title":"Drugs"},{"key":"3483_CR9","unstructured":"Long-acting injectable cabotegravir is highly effective for the prevention of HIV infection in cisgender men and transgender women who have sex with men | The HIV Prevention Trials Network. https:\/\/www.hptn.org\/news-and-events\/press-releases\/long-acting-injectable-cabotegravir-highly-effective-prevention-hiv. Accessed 18 Jun 2020."},{"key":"3483_CR10","unstructured":"World Health Organization. Trial results reveal that long-acting injectable cabotegravir as PrEP is highly effective in preventing HIV acquisition in women. https:\/\/www.who.int\/news\/item\/09-11-2020-trial-results-reveal-that-long-acting-injectable-cabotegravir-as-prep-is-highly-effective-in-preventing-hiv-acquisition-in-women. Accessed 9 Nov 2020."},{"key":"3483_CR11","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1007\/s10461-020-02808-2","volume":"24","author":"EE Tolley","year":"2020","unstructured":"Tolley EE, Zangeneh SZ, Chau G, Eron J, Grinsztejn B, Humphries H, et al. Acceptability of long-acting injectable cabotegravir (CAB LA) in HIV-uninfected individuals: HPTN 077. AIDS Behav. 2020;24:2520\u201331.","journal-title":"AIDS Behav"},{"key":"3483_CR12","doi-asserted-by":"publisher","first-page":"e331","DOI":"10.1016\/S2352-3018(17)30068-1","volume":"4","author":"M Markowitz","year":"2017","unstructured":"Markowitz M, Frank I, Grant RM, Mayer KH, Elion R, Goldstein D, et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV. 2017;4:e331\u201340.","journal-title":"Lancet HIV"},{"key":"3483_CR13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/15284336.2018.1511346","volume":"19","author":"MI Murray","year":"2018","unstructured":"Murray MI, Markowitz M, Frank I, Grant RM, Mayer KH, Hudson KJ, et al. Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: patient perspectives from the ECLAIR trial. HIV Clin Trials. 2018;19:129\u201338.","journal-title":"HIV Clin Trials"},{"key":"3483_CR14","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1007\/s10461-017-2017-x","volume":"22","author":"D Kerrigan","year":"2018","unstructured":"Kerrigan D, Mantsios A, Grant R, Markowitz M, Defechereux P, La Mar M, et al. Expanding the menu of HIV prevention options: a qualitative study of experiences with long-acting injectable cabotegravir as prep in the context of a phase II trial in the united states. AIDS Behav. 2018;22:3540\u20139.","journal-title":"AIDS Behav"},{"key":"3483_CR15","unstructured":"ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV. https:\/\/viivhealthcare.com\/en-gb\/media\/press-releases\/2021\/may\/viiv-healthcare-initiates-rolling\/. Accessed 13 Sep 2021."},{"key":"3483_CR16","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1080\/09540121.2019.1587356","volume":"31","author":"KB Biello","year":"2019","unstructured":"Biello KB, Edeza A, Salhaney P, Biancarelli DL, Mimiaga MJ, Drainoni ML, et al. A missing perspective: injectable pre-exposure prophylaxis for people who inject drugs. AIDS Care. 2019;31:1214\u201320.","journal-title":"AIDS Care"},{"key":"3483_CR17","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1080\/09540121.2019.1587352","volume":"31","author":"KHA Footer","year":"2019","unstructured":"Footer KHA, Lim S, Rael CT, Greene GJ, Carballa-Di\u00e9guez A, Giguere R, et al. Exploring new and existing PrEP modalities among female sex workers and women who inject drugs in a U.S. city. AIDS Care. 2019;31:1207\u201313.","journal-title":"AIDS Care"},{"key":"3483_CR18","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1089\/apc.2018.0198","volume":"33","author":"JM Simoni","year":"2019","unstructured":"Simoni JM, Beima-Sofie K, Mohamed ZH, Christodoulou J, Tapia K, Graham SM, et al. Long-acting injectable antiretroviral treatment acceptability and preferences: a qualitative study among us providers, adults living with HIV, and parents of youth living with HIV. AIDS Pat Care STDs. 2019;33:104\u201311.","journal-title":"AIDS Pat Care STDs"},{"issue":"1","key":"3483_CR19","doi-asserted-by":"publisher","first-page":"e0190487","DOI":"10.1371\/journal.pone.0190487","volume":"13","author":"D Kerrigan","year":"2018","unstructured":"Kerrigan D, Mantsios A, Gorgolas M, Montes M-L, Pulido F, Brinson C, et al. Experiences with long acting injectable ART: a qualitative study among PLHIV participating in a phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain. PLoS ONE. 2018;13(1):e0190487.","journal-title":"PLoS ONE"},{"key":"3483_CR20","doi-asserted-by":"publisher","first-page":"e0200296","DOI":"10.1371\/journal.pone.0200296","volume":"13","author":"K Meyers","year":"2018","unstructured":"Meyers K, Wu Y, Brill A, Sandfort T, Golub SA. To switch or not to switch: Intentions to switch to injectable PrEP among gay and bisexual men with at least twelve months oral PrEP experience. PLoS ONE. 2018;13:e0200296.","journal-title":"PLoS ONE"},{"key":"3483_CR21","doi-asserted-by":"publisher","first-page":"e25408","DOI":"10.1002\/jia2.25408","volume":"22","author":"EE Tolley","year":"2019","unstructured":"Tolley EE, Li S, Zangeneh SZ, Atujuna M, Musara P, Justman J, et al. Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076). J Int AIDS Soc. 2019;22:e25408.","journal-title":"J Int AIDS Soc"},{"key":"3483_CR22","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/QAI.0000000000002337","volume":"84","author":"MM Philbin","year":"2020","unstructured":"Philbin MM, Parish C, Kinnard EN, Reed SE, Kerrigan D, Alcaide M, et al. A multi-site study of women living with HIV\u2019s perceived barriers to, and interest in, long-acting injectable anti-retroviral therapy. J Acquir Immune Defic Syndr. 2020;84:263\u201370.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"3483_CR23","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/QAI.0000000000001896","volume":"80","author":"ED Weld","year":"2019","unstructured":"Weld ED, Rana MS, Dallas RH, Camacho-Gonzalez AF, Ryscavage P, Gaur AH, et al. Interest of youth living with HIV in long-acting rntiretrovirals. J Acquir Immune Defic Syndr. 2019;80:190\u20137.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"3483_CR24","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1007\/s10508-017-1049-7","volume":"47","author":"KB Biello","year":"2018","unstructured":"Biello KB, Hosek S, Drucker MT, Belzer M, Mimiaga MJ, Marrow E, et al. Preferences for injectable prep among young U.S. cisgender men and transgender women and men who have sex with men. Arch Sex Behav. 2018;47:2101\u20137.","journal-title":"Arch Sex Behav"},{"key":"3483_CR25","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s10461-020-03023-9","volume":"25","author":"MM Philbin","year":"2020","unstructured":"Philbin MM, Parish C, Kinnard E, Reed R, Kerrigan D, Alcaide M, et al. Attitudes towards long-acting injectable pre-exposure prophylaxis (PrEP) among women participating in the Women\u2019s Interagency HIV Study (WIHS): a qualitative study across six United States cities. AIDS Behav. 2020;25:667\u201378.","journal-title":"AIDS Behav"},{"key":"3483_CR26","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/COH.0000000000000601","volume":"15","author":"D Castor","year":"2020","unstructured":"Castor D, Meyers K, Allen S. The only way is up: priorities for implementing long-acting antiretrovirals for HIV prevention and treatment. Curr Opin HIV AIDS. 2020;15:73\u201380.","journal-title":"Curr Opin HIV AIDS"},{"key":"3483_CR27","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s40265-020-01284-1","volume":"80","author":"AI Rana","year":"2020","unstructured":"Rana AI, Castillo-Mancilla JR, Tashima KT, Landovitz RL. Advances in long-acting agents for the treatment of HIV infection. Drugs. 2020;80:535\u201345.","journal-title":"Drugs"},{"key":"3483_CR28","doi-asserted-by":"crossref","unstructured":"Dub\u00e9 K, Campbell DM, Perry KE, Kanazawa JT, Saberi P, Sauceda JA, et al. Reasons people living with HIV might prefer oral daily antiretroviral therapy, long-acting formulations, or future HIV remission options. AIDS Res Hum Retroviruses. 2020.","DOI":"10.1089\/aid.2020.0107"},{"key":"3483_CR29","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1007\/s10461-020-02918-x","volume":"24","author":"A Mantsios","year":"2020","unstructured":"Mantsios A, Murray M, Karver TS, Davis W, Margolis D, Kumar P, et al. efficacy and freedom: patient experiences with the transition from daily oral to long-acting injectable antiretroviral therapy to treat HIV in the context of phase 3 trials. AIDS Behav. 2020;24:3473\u201381.","journal-title":"AIDS Behav"},{"key":"3483_CR30","first-page":"179","volume":"11","author":"C Fernandez","year":"2019","unstructured":"Fernandez C, van Halsema CL. Evaluating cabotegravir\/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential. HIV AIDS (Auckl). 2019;11:179\u201392.","journal-title":"HIV AIDS (Auckl)"},{"key":"3483_CR31","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","volume":"385","author":"RJ Landovitz","year":"2021","unstructured":"Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385:595\u2013608.","journal-title":"N Engl J Med"},{"key":"3483_CR32","unstructured":"HIV Prevention Trials Network I. HPTN 084: A phase 3 double blind safety and efficacy study of long-acting injectable cabotegravir compared to daily oral TDF\/FTC for pre-exposure prophylaxis in HIV-uninfected women. 2019. https:\/\/www.hptn.org\/sites\/default\/files\/inline-files\/HPTN%20084%20Protocol%2C%20FINAL%2C%20v2.0%20of%206Nov2019_web.pdf"},{"key":"3483_CR33","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1056\/NEJMe2002199","volume":"382","author":"JS Currier","year":"2020","unstructured":"Currier JS. Monthly injectable antiretroviral therapy\u2014version 1.0 of a new treatment approach. N Engl J Med. 2020;382:1164\u20135.","journal-title":"N Engl J Med"},{"key":"3483_CR34","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12905-020-01011-8","volume":"20","author":"L Benning","year":"2020","unstructured":"Benning L, Mantsios A, Kerrigan D, Coleman JS, Golub E, Blackstock O, et al. Examining adherence barriers among women with HIV to tailor outreach for long-acting injectable antiretroviral therapy. BMC Women\u2019s Health. 2020;20:152.","journal-title":"BMC Women\u2019s Health"},{"key":"3483_CR35","first-page":"1","volume":"1","author":"A Mantsios","year":"2020","unstructured":"Mantsios A, Murray M, Karver TS, Davis W, Margolis D, Kumar P, et al. \u201cI feel empowered\u201d: women\u2019s perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and Spain. Cult Health Sex. 2020;1:1\u201313.","journal-title":"Cult Health Sex"},{"key":"3483_CR36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1258\/jhsrp.2009.009081","volume":"15","author":"S Buetow","year":"2010","unstructured":"Buetow S. Thematic analysis and its reconceptualization as \u2018saliency analysis.\u2019 Health Serv Res Policy. 2010;15:123\u20135.","journal-title":"Health Serv Res Policy"},{"key":"3483_CR37","doi-asserted-by":"crossref","unstructured":"Glaser BG, Strauss AL. The discovery of grounded theory: strategies for qualitative research. 1967.","DOI":"10.1097\/00006199-196807000-00014"},{"key":"3483_CR38","first-page":"31","volume":"10","author":"K MacQueen","year":"1998","unstructured":"MacQueen K, McLellan E, Kay K. Codebook development for team-based qualitative analysis. Cult Anthropol Methods. 1998;10:31\u20136.","journal-title":"Cult Anthropol Methods"},{"key":"3483_CR39","doi-asserted-by":"crossref","unstructured":"A Qualitative Exploration of Women\u2019s Interest in Long-Acting Injectable antiretroviral therapy across six cities in the Women\u2019s Interagency HIV Study: intersections with current and past injectable medication and substance use. AIDS Patient Care STDs. 2021;35:23\u201330.","DOI":"10.1089\/apc.2020.0164"},{"key":"3483_CR40","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1007\/s10461-015-1209-5","volume":"20","author":"MM Holstad","year":"2016","unstructured":"Holstad MM, Spangler S, Higgins M, Dalmida SG, Sharma S. Psychosocial characteristics associated with both antiretroviral therapy adherence and risk behaviors in women living with HIV. AIDS Behav. 2016;20:1084\u201396.","journal-title":"AIDS Behav"},{"key":"3483_CR41","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1089\/apc.2008.0161","volume":"23","author":"D Merenstein","year":"2009","unstructured":"Merenstein D, Schneider MF, Cox C, Schwartz R, Weber K, Robison E, et al. Association of child care burden and household composition with adherence to highly active antiretroviral therapy in the Women\u2019s Interagency HIV Study. AIDS Pat Care STDs. 2009;23:289\u201396.","journal-title":"AIDS Pat Care STDs"},{"key":"3483_CR42","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1080\/09540121.2016.1258451","volume":"29","author":"T Cornelius","year":"2017","unstructured":"Cornelius T, Jones M, Merly C, Welles B, Kalichman MO, Kalichman SC. Impact of food, housing, and transportation insecurity on ART adherence: a hierarchical resources approach. AIDS Care. 2017;29:449\u201357.","journal-title":"AIDS Care"},{"key":"3483_CR43","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s10461-012-0364-1","volume":"17","author":"K MacDonell","year":"2013","unstructured":"MacDonell K, Naar-King S, Huszti H, Belzer M. Barriers to medication adherence in behaviorally and perinatally infected youth living with HIV. AIDS Behav. 2013;17:86\u201393.","journal-title":"AIDS Behav"},{"key":"3483_CR44","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/13548506.2014.945601","volume":"20","author":"KR Claborn","year":"2015","unstructured":"Claborn KR, Meier E, Miller MB, Leffingwell TR. A systematic review of treatment fatigue among HIV-infected patients prescribed antiretroviral therapy. Psychol Health Med. 2015;20:255\u201365.","journal-title":"Psychol Health Med"},{"key":"3483_CR45","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1186\/s12879-018-3463-4","volume":"18","author":"D Sidebottom","year":"2018","unstructured":"Sidebottom D, Ekstr\u00f6m AM, Str\u00f6mdahl S. A systematic review of adherence to oral pre-exposure prophylaxis for HIV\u2014how can we improve uptake and adherence? BMC Infect Dis. 2018;18:581.","journal-title":"BMC Infect Dis"},{"key":"3483_CR46","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1097\/QAD.0000000000002227","volume":"33","author":"RH Remien","year":"2019","unstructured":"Remien RH, Stirratt MJ, Nguyen N, Robbins RN, Pala AN, Mellins CA. Mental health and HIV\/AIDS: the need for an integrated response. AIDS. 2019;33:1411\u201320.","journal-title":"AIDS"},{"issue":"12","key":"3483_CR47","doi-asserted-by":"publisher","first-page":"e114700","DOI":"10.1371\/journal.pone.0114700","volume":"9","author":"K Meyers","year":"2014","unstructured":"Meyers K, Rodriguez K, Moeller RW, Gratch I, Markowitz M, Halkitis PN. High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy. PLoS ONE. 2014;9(12):e114700.","journal-title":"PLoS ONE"},{"key":"3483_CR48","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.cbpra.2013.11.001","volume":"21","author":"IB Thurston","year":"2014","unstructured":"Thurston IB, Bogart LM, Wachman M, Closson EF, Skeer MR, Mimiaga MJ. Adaptation of an HIV medication adherence intervention for adolescents and young adults. Cogn Behav Pract. 2014;21:191\u2013205.","journal-title":"Cogn Behav Pract"},{"key":"3483_CR49","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.annepidem.2018.06.005","volume":"28","author":"AJ Siegler","year":"2018","unstructured":"Siegler AJ, Mouhanna F, Giler RM, Weiss K, Pembleton E, Guest J, et al. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States. Ann Epidemiol. 2018;28:841\u20139.","journal-title":"Ann Epidemiol"},{"key":"3483_CR50","unstructured":"CDC. HIV and Youth. Centers for Disease Control and Prevention. http:\/\/www.cdc.gov\/hiv\/group\/age\/youth\/index.html (2020) Accessed 10 Jun 2020."},{"key":"3483_CR51","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S0277-9536(99)00390-1","volume":"50","author":"WH Courtenay","year":"2000","unstructured":"Courtenay WH. Constructions of masculinity and their influence on men\u2019s well-being: a theory of gender and health. Soc Sci Med. 2000;50:1385\u2013401.","journal-title":"Soc Sci Med"},{"key":"3483_CR52","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1177\/1524839918778835","volume":"20","author":"ME Aleshire","year":"2019","unstructured":"Aleshire ME, Ashford K, Fallin-Bennett A, Hatcher J. Primary care providers\u2019 attitudes related to LGBTQ people: a narrative literature review. Health Promot Prac. 2019;20:173\u201387.","journal-title":"Health Promot Prac"},{"key":"3483_CR53","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.socscimed.2018.05.020","volume":"208","author":"AJ Martos","year":"2018","unstructured":"Martos AJ, Wilson PA, Gordon AR, Lightfoot M, Meyer IH. \u201cLike finding a unicorn\u201d: Healthcare preferences among lesbian, gay, and bisexual people in the United States. Soc Sci Med. 2018;208:126\u201333.","journal-title":"Soc Sci Med"},{"key":"3483_CR54","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1007\/s10508-018-1211-x","volume":"47","author":"MM Philbin","year":"2018","unstructured":"Philbin MM, Parker CM, Parker RG, Wilson PA, Garcia J, Hirsch JS. Gendered social institutions and preventive healthcare seeking for black men who have sex with men: the promise of biomedical HIV prevention. Arch Sex Behav. 2018;47:2091\u2013100.","journal-title":"Arch Sex Behav"},{"key":"3483_CR55","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/15381501.2020.1767749","volume":"19","author":"J Jaiswal","year":"2020","unstructured":"Jaiswal J, Francis MD, Singer SN, Dunlap KB, Cox AB, Greene R. \u201cWorn out\u201d: coping strategies for managing antiretroviral treatment fatigue among urban people of color living with HIV who were recently disengaged from outpatient HIV care. J HIV\/AIDS Soc Serv. 2020;19:173\u201387.","journal-title":"J HIV\/AIDS Soc Serv"},{"key":"3483_CR56","doi-asserted-by":"publisher","first-page":"e787","DOI":"10.1542\/peds.2007-1586","volume":"121","author":"DJ Merenstein","year":"2008","unstructured":"Merenstein DJ, Schneider MF, Cox C, Schwartz R, Weber K, Robison E, et al. Association between living with children and adherence to highly active antiretroviral therapy in the Women\u2019s Interagency HIV Study. Pediatrics. 2008;121:e787\u201393.","journal-title":"Pediatrics"},{"key":"3483_CR57","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/COH.0000000000000166","volume":"10","author":"JE Myers","year":"2015","unstructured":"Myers JE, Ellman TM, Westhoff C. Injectable agents for pre-exposure prophylaxis: lessons learned from contraception to inform HIV prevention. Cur Opin HIV AIDS. 2015;10:271\u20137.","journal-title":"Cur Opin HIV AIDS"},{"key":"3483_CR58","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.2105\/AJPH.90.7.1138","volume":"90","author":"MD Stein","year":"2000","unstructured":"Stein MD, Crystal S, Cunningham WE, Ananthanarayanan A, Andersen RM, Turner BJ, et al. Delays in seeking HIV care due to competing caregiver responsibilities. Am J Public Health. 2000;90:1138\u201340.","journal-title":"Am J Public Health"},{"key":"3483_CR59","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1080\/09540121.2017.1300628","volume":"29","author":"S Peitzmeier","year":"2017","unstructured":"Peitzmeier S, Tomko C, Wingo E, Sawyer A, Sherman S, Glass N, et al. Acceptability of pre-exposure prophylaxis and vaginal rings for HIV prevention among female sex workers in Baltimore. MD AIDS Care. 2017;29:1453\u20137.","journal-title":"MD AIDS Care"},{"key":"3483_CR60","unstructured":"Sex Workers | HIV by Group | HIV\/AIDS | CDC. http:\/\/www.cdc.gov\/hiv\/group\/sexworkers.html (2020) Accessed 10 Jun 2020."},{"key":"3483_CR61","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1007\/s10461-019-02733-z","volume":"24","author":"JL Glick","year":"2020","unstructured":"Glick JL, Russo R, Jivapong B, Rosman L, Pelaez D, Footer KHA, et al. The PrEP care continuum among cisgender women who sell sex and\/or use drugs globally: a systematic review. AIDS Behav. 2020;24:1312\u201333.","journal-title":"AIDS Behav"},{"key":"3483_CR62","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/COH.0000000000000628","volume":"15","author":"E Mendenhall","year":"2020","unstructured":"Mendenhall E, Singer M. What constitutes a syndemic? Methods, contexts, and framing from 2019. Curr Opin HIV AIDS. 2020;15:213\u20137.","journal-title":"Curr Opin HIV AIDS"},{"key":"3483_CR63","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1080\/09540121.2019.1626338","volume":"32","author":"JP Jain","year":"2020","unstructured":"Jain JP, Strathdee SA, Patterson TL, Semple SJ, Harvey-Vera A, Magis-Rodr\u00edguez C, et al. Perceived barriers to pre-exposure prophylaxis use and the role of syndemic factors among female sex workers in the Mexico-United States border region: a latent class analysis. AIDS Care. 2020;32:557\u201366.","journal-title":"AIDS Care"},{"key":"3483_CR64","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/01.qai.0000248333.44449.ea","volume":"43","author":"GH Friedland","year":"2006","unstructured":"Friedland GH. HIV medication adherence: the intersection of biomedical, behavioral, and social science research and clinical practice. J Acquir Immune Defic Syndr. 2006;43:S3.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"3483_CR65","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0010-7824(97)00140-6","volume":"56","author":"C Paul","year":"1997","unstructured":"Paul C, Skegg DC, Williams S. Depot medroxyprogesterone acetate. Patterns of use and reasons for discontinuation. Contraception. 1997;56:209\u201314.","journal-title":"Contraception"},{"key":"3483_CR66","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.2105\/AJPH.87.9.1532","volume":"87","author":"AR Davidson","year":"1997","unstructured":"Davidson AR, Kalmuss D, Cushman LF, Romero D, Heartwell S, Rulin M. Injectable contraceptive discontinuation and subsequent unintended pregnancy among low-income women. Am J Public Health. 1997;87:1532\u20134.","journal-title":"Am J Public Health"},{"key":"3483_CR67","doi-asserted-by":"publisher","first-page":"ofz365","DOI":"10.1093\/ofid\/ofz365","volume":"6","author":"JP Havens","year":"2019","unstructured":"Havens JP, Scarsi KK, Sayles H, Klepser DG, Swindells S, Bares SH. Acceptability and feasibility of a pharmacist-led human immunodeficiency virus pre-exposure prophylaxis program in the midwestern United States. Open Forum Infect Dis. 2019;6:ofz365.","journal-title":"Open Forum Infect Dis"},{"key":"3483_CR68","unstructured":"Centers for Disease Control and Prevention. Women | Gender | HIV by Group | HIV\/AIDS | CDC [Internet]. CDC.gov. https:\/\/www.cdc.gov\/hiv\/group\/gender\/women\/index.html (2018) Accessed 21 May 2018."},{"key":"3483_CR69","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/QAI.0000000000001935","volume":"80","author":"TC Willie","year":"2019","unstructured":"Willie TC, Stockman JK, Keene DE, Calabrese SK, Alexander KA, Kershaw TS. Social networks and its impact on women\u2019s awareness, interest, and uptake of HIV pre-exposure prophylaxis (PrEP): implications for women experiencing intimate partner violence. J Acquir Immune Defic Syndr. 2019;80:386\u201393.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"3483_CR70","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s11904-019-00450-9","volume":"16","author":"MR Beymer","year":"2019","unstructured":"Beymer MR, Holloway IW, Pulsipher C, Landovitz RJ. Current and future PrEP medications and modalities: on-demand, injectables, and topicals. Curr HIV\/AIDS Rep. 2019;16:349\u201358.","journal-title":"Curr HIV\/AIDS Rep"}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-021-03483-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-021-03483-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-021-03483-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T03:49:34Z","timestamp":1699674574000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-021-03483-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,14]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["3483"],"URL":"https:\/\/doi.org\/10.1007\/s10461-021-03483-7","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,14]]},"assertion":[{"value":"22 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Adaora A. Adimora-has received funding from ViiV, Merck, and Gilead, including a grant from Gilead. For the remaining authors none were declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"IRB approval was obtained at all participating sites prior to interview initiation. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study prior to the interview.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}}]}}